Literature DB >> 33643266

Codon Usage and Adenovirus Fitness: Implications for Vaccine Development.

Judit Giménez-Roig1, Estela Núñez-Manchón1, Ramon Alemany2, Eneko Villanueva3, Cristina Fillat1,4,5.   

Abstract

Vaccination is the most effective method to date to prevent viral diseases. It intends to mimic a naturally occurring infection while avoiding the disease, exposing our bodies to viral antigens to trigger an immune response that will protect us from future infections. Among different strategies for vaccine development, recombinant vaccines are one of the most efficient ones. Recombinant vaccines use safe viral vectors as vehicles and incorporate a transgenic antigen of the pathogen against which we intend to generate an immune response. These vaccines can be based on replication-deficient viruses or replication-competent viruses. While the most effective strategy involves replication-competent viruses, they must be attenuated to prevent any health hazard while guaranteeing a strong humoral and cellular immune response. Several attenuation strategies for adenoviral-based vaccine development have been contemplated over time. In this paper, we will review them and discuss novel approaches based on the principle that protein synthesis from individual genes can be modulated by codon usage bias manipulation. We will summarize vaccine approaches that consider recoding of viral proteins to produce adenoviral attenuation and recoding of the transgene antigens for both viral attenuation and efficient viral epitope expression.
Copyright © 2021 Giménez-Roig, Núñez-Manchón, Alemany, Villanueva and Fillat.

Entities:  

Keywords:  adenovirus-based vaccines; codon optimization; codon usage bias; live-attenuated vaccines; viral attenuation

Year:  2021        PMID: 33643266      PMCID: PMC7902882          DOI: 10.3389/fmicb.2021.633946

Source DB:  PubMed          Journal:  Front Microbiol        ISSN: 1664-302X            Impact factor:   5.640


  66 in total

Review 1.  Selection on codon bias.

Authors:  Ruth Hershberg; Dmitri A Petrov
Journal:  Annu Rev Genet       Date:  2008       Impact factor: 16.830

2.  Genetic inactivation of poliovirus infectivity by increasing the frequencies of CpG and UpA dinucleotides within and across synonymous capsid region codons.

Authors:  Cara C Burns; Ray Campagnoli; Jing Shaw; Annelet Vincent; Jaume Jorba; Olen Kew
Journal:  J Virol       Date:  2009-07-15       Impact factor: 5.103

Review 3.  Molecular mechanisms for enhanced DNA vaccine immunogenicity.

Authors:  Lei Li; Nikolai Petrovsky
Journal:  Expert Rev Vaccines       Date:  2015-12-28       Impact factor: 5.217

4.  Immunodominance of Adenovirus-Derived CD8+ T Cell Epitopes Interferes with the Induction of Transgene-Specific Immunity in Adenovirus-Based Immunization.

Authors:  Dominik Schöne; Camilla Patrizia Hrycak; Sonja Windmann; Dennis Lapuente; Ulf Dittmer; Matthias Tenbusch; Wibke Bayer
Journal:  J Virol       Date:  2017-09-27       Impact factor: 5.103

Review 5.  Factors Which Contribute to the Immunogenicity of Non-replicating Adenoviral Vectored Vaccines.

Authors:  Lynda Coughlan
Journal:  Front Immunol       Date:  2020-05-19       Impact factor: 7.561

6.  Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.

Authors:  Pedro M Folegatti; Katie J Ewer; Parvinder K Aley; Brian Angus; Stephan Becker; Sandra Belij-Rammerstorfer; Duncan Bellamy; Sagida Bibi; Mustapha Bittaye; Elizabeth A Clutterbuck; Christina Dold; Saul N Faust; Adam Finn; Amy L Flaxman; Bassam Hallis; Paul Heath; Daniel Jenkin; Rajeka Lazarus; Rebecca Makinson; Angela M Minassian; Katrina M Pollock; Maheshi Ramasamy; Hannah Robinson; Matthew Snape; Richard Tarrant; Merryn Voysey; Catherine Green; Alexander D Douglas; Adrian V S Hill; Teresa Lambe; Sarah C Gilbert; Andrew J Pollard
Journal:  Lancet       Date:  2020-07-20       Impact factor: 79.321

Review 7.  Non-Human Primate-Derived Adenoviruses for Future Use as Oncolytic Agents?

Authors:  Selas T F Bots; Rob C Hoeben
Journal:  Int J Mol Sci       Date:  2020-07-08       Impact factor: 5.923

8.  An adenovirus-vectored COVID-19 vaccine confers protection from SARS-COV-2 challenge in rhesus macaques.

Authors:  Liqiang Feng; Qian Wang; Chao Shan; Chenchen Yang; Ying Feng; Jia Wu; Xiaolin Liu; Yiwu Zhou; Rendi Jiang; Peiyu Hu; Xinglong Liu; Fan Zhang; Pingchao Li; Xuefeng Niu; Yichu Liu; Xuehua Zheng; Jia Luo; Jing Sun; Yingying Gu; Bo Liu; Yongcun Xu; Chufang Li; Weiqi Pan; Jincun Zhao; Changwen Ke; Xinwen Chen; Tao Xu; Nanshan Zhong; Suhua Guan; Zhiming Yuan; Ling Chen
Journal:  Nat Commun       Date:  2020-08-21       Impact factor: 17.694

9.  Deep splicing plasticity of the human adenovirus type 5 transcriptome drives virus evolution.

Authors:  I'ah Donovan-Banfield; Andrew S Turnell; Julian A Hiscox; Keith N Leppard; David A Matthews
Journal:  Commun Biol       Date:  2020-03-13

10.  Synonymous genome recoding: a tool to explore microbial biology and new therapeutic strategies.

Authors:  Miguel Angel Martínez; Ana Jordan-Paiz; Sandra Franco; Maria Nevot
Journal:  Nucleic Acids Res       Date:  2019-11-18       Impact factor: 16.971

View more
  1 in total

Review 1.  Environmental Risk Assessment of Recombinant Viral Vector Vaccines against SARS-Cov-2.

Authors:  Aline Baldo; Amaya Leunda; Nicolas Willemarck; Katia Pauwels
Journal:  Vaccines (Basel)       Date:  2021-05-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.